Dendritic cells (DC) are the most potent antigen-presenting cells known, currently tested for vaccination studies in cancer patients. The use of tumor-derived RNA to load DC overcomes the requirement of defined HLA types and the identification of tumor antigens expressed by the tumors. Here, we show that human monocyte-derived DC generated under serum-free conditions by GM-CSF, IL-4 and TNF-a acquire a mature phenotype and expression of the chemokine receptor CCR-7, which plays a pivotal role in DC migration to the afferent lymph nodes. We demonstrate the feasibility of total RNA transfection into such DC using the renal cell carcinoma (RCC) cell line N43-EGFP, which was stably transfected with an EGFP-encoding vector. Moreover, we show that DC transfected with RNA from colorectal cancer cells present HLA class I-restricted antigenic epitopes to induce a primary antitumor CTL response in vitro. Interestingly, the CTL induced by SW480 RNA also recognized another colon cancer line, HCT116, and the RCC line A498. Our results confirm the feasibility of total RNA transfection of serum-free generated DC for the induction of CTL against colon cancer and RCC cells, and support the relevance of shared tumor rejection epitopes between colorectal cancer and RCC.
C
ancer of the colon is a highly treatable and often curable disease when localized to the bowel. Surgery is the primary form of treatment and results in the cure of approximately 50% of patients. However, recurrence following surgery is a major problem and often is the ultimate cause of death. Recent studies by Vermorken et al 1, 2 indicate that patients with early-stage colon cancer could benefit from an immunotherapeutic approach. Active specific immunotherapy of stage II colon cancer patients by means of irradiated autologous tumor cell/ Bacillus Calmette-Guerin vaccine led to a significantly longer recurrence-free period and 61% risk reduction for recurrences. 1 Dendritic cells (DC) are the most potent antigen (Ag)-presenting cells (APC) known, with the capacity to initiate primary immune responses. 3 Preliminary vaccination studies in cancer patients showed that induction of immune responses against tumor-associated antigens (TAA) by antigen-loaded DC is feasible with no or mild side effects. [4] [5] [6] Moreover, in some cases, objective clinical responses following vaccine administration were observed. However, a broad application of DC-based vaccination approaches is impeded by the limited number of TAA identified so far, by the restriction to defined HLA alleles for immunizations with peptides, and by the requirement of large amounts of tumor tissue for approaches using whole tumor cells, that is tumor lysates, apoptotic tumor cells.
Loading DC with RNA derived from tumor cells may overcome such limitations since it bypasses HLA restrictions and the necessity to previously identify the antigens expressed by the tumor. [7] [8] [9] In animal models, vaccination of tumor-bearing mice using DC loaded with autologous tumor-mRNA engenders protective immunity. 10, 11 Moreover, sufficient amounts of RNA for vaccine preparation can be generated amplifying RNA isolated from limiting amounts of tumor tissue, like those obtained from surgically removed tumor sections or from needle biopsyderived material. 7 This approach, pioneered by Gilboa et al, showed promising results for the induction of antitumor cytotoxic T-lymphocyte (CTL) responses against a variety of human solid tumors, including prostate, 8 lung, colorectal cancer 9 and renal cell carcinoma (RCC). 8 Here, we report that human monocyte-derived DC generated under serum-free conditions acquire potent immunostimulatory capacity and expression of CCR-7, which drives DC migration to the afferent lymph nodes. Once transfected with RNA isolated from colon cancer cells, these DC stimulate CTL that efficiently recognize the parental cells and crossreact with an RCC cell line, possibly because of shared tumor antigens.
Materials and methods

Tumor cell lines
Tumor cell lines used in the experiments were grown in RP10 medium (RPMI 1640 supplemented with 10% heatinactivated fetal calf serum (FCS), 2 mmol/l l-glutamine, 50 mmol/l 2-mercaptoethanol and antibiotics). The following HLA-A2-expressing tumor cell lines were used: N43, A498 (RCC), SW480 and HCT116 (colon carcinoma). Croft (HLA-A2) is an EBV-immortalized B cell line and was kindly provided by OJ Finn (Pittsburgh, PA, USA).
Cell isolation and generation of DC from adherent peripheral blood mononuclear cells Generation of DC from peripheral blood monocytes was performed as described previously. [13] [14] [15] In brief, peripheral blood mononuclear cells (PBMC) were isolated by Ficoll/ Paque (Life Technologies, Inc.) density gradient centrifugation of heparinized blood obtained from buffy coat preparations of healthy volunteers. Cells were seeded (1 Â 10 7 cells/3 ml/well) into six-well plates (Costar, Cambridge, MA, USA) in X-VIVO 20 (BIO Whittaker, Walkersville, MD, USA). After 2 h of incubation at 371C, nonadherent cells were removed, and the adherent blood monocytes were cultured in X-VIVO 20 supplemented with the following cytokines: human recombinant GM-CSF (Leukomax; 100 ng/ml; Novartis, Nu¨rnberg, Germany), IL-4 (1000 IU/ml) and TNF-a (10 ng/ml), both purchsed from R&D Systems (Minneapolis, MN, USA). The phenotype of the generated DC was analyzed by flow cytometry after 7 days of culture. DC were enumerated as lineage (CD3, CD14, CD19) negative, HLA-DR bright, CD1a and/or CD83 positive, and purity was confirmed by morphology.
Immunostaining
Cell staining was performed using FITC-or PE-conjugated mouse monoclonal antibodies against CD86 (PharMingen, Hamburg, Germany), CD80, HLA-DR, CD14, CD3, CD19 (Becton Dickinson), CD83 (CoulterImmunotech, Hamburg, Germany) and CD1a (clone NA1/34, Dako A/S, Denmark). Appropriate mouse IgG isotypes were used as controls (Becton Dickinson). Antihuman CCR-1 and anti-human CCR-2 were purchased from R&D Systems. Anti-human CCR-5 and anti-human CCR-7 were from BD Pharmingen. The samples were analyzed by flow cytometry on a FACScan (Becton Dickinson, Heidelberg, Germany).
RNA isolation
Total RNA was isolated from tumor cell lysates using RNeasy TM Maxi anion-exchange spin columns (Qiagen) according to the protocol for isolation of total RNA provided by the manufacturer. RNA integrity was tested using a standard protocol to amplify a gene-specific Abl sequence, as previously described. 16 
Stable transfection of N43 Cells
The RCC cell line N43 was cultured and expanded in RP10 medium. The cells were transfected with the expression vector pEGFP-N1 (BD Biosciences Clontech, Heidelberg, Germany) using FuGENE 6t transfection reagent (Roche Molecular Biochemicals, Mannheim, Germany) according to the protocol provided by the manufacturer. For positive selection of stable transfectants, the cells were selected and cultured in RP10 medium containing the antibiotic geneticin (Invitrogen, Karlsruhe, Germany) at a concentration of 500 mg/ml.
Electroporation of DC
Prior to electroporation on day 6, DC were washed twice with serum-free X-VIVO 20 medium and resuspended to a final concentration of 2 Â 10 7 cells/ml. Subsequently, 200 ml of the cell suspension was mixed with 20 mg of total RNA and electroporated in a 4 mm cuvette using an Easyject Plust unit (Peqlab, Erlangen, Germany). The physical parameters were a voltage of 300 V, capacitance of 150 mF, a resistance of 1540 W and a pulse time of 231 ms. 17 After electroporation, the cells were immediately transferred into X-VIVO 20 supplemented with GM-CSF, IL-4 and TNF-a and returned to the incubator. The viability of the cells after electroporation was more than 80%.
Induction of tumor-specific CTL using DC transfected with tumor RNA DC transfected with SW480 or HCT116 RNA were used for CTL induction 24 h after electroporation. For CTL induction, 3 Â 10 5 DC transfected with tumor RNA were incubated with 3 Â 10 6 autologous PBMC. Additional DC transfected with RNA were stored at À801C, to be used later for restimulation. After 7 days of culture, cells were restimulated with autologous RNA-transfected DC, and 1 ng/ml human recombinant IL-2 (R&D Systems, Minneapolis, MN, USA) was added on days 1 and 3. The cytolytic activity of the induced CTL was analyzed on day 5 after restimulation in a standard 51 Cr-release assay.
CTL assay
The standard 51
Cr-labeled release assay was performed as described elsewhere. [13] [14] [15] 18 Briefly, target cells were labeled with 51 Cr sodium chromate in RP10 medium for 1 h at 371C. Cells (10 4 ) were transferred to a well of a round-bottomed 96-well plate. Varying numbers of CTL were added to give a final volume of 200 ml and incubated for 4 h at 371C. At the end of the assay, supernatants (50 ml/well) were harvested and counted in a b-plate counter. The percentage of specific lysis was calculated as 100 Â (experimental releaseÀspontaneous release/maximal releaseÀspontaneous release). Spontaneous and maximal releases were determined in the presence of either RP10 medium or 1% Triton X-100, respectively. HLA class I restriction of tumor cell lysis was further assessed by blocking HLA class I molecules using a monoclonal antibody (W01-052, c ¼ 20 mg/ml; generously provided by S Stevanovic, Tu¨bingen, Germany).
Results
Monocyte-derived DC generated under serum-free conditions by GM-CSF, IL-4 and TNF-a present a mature phenotype and CCR-7 expression DC were generated from adherent monocytes of healthy donors in the presence of GM-CSF, IL-4 and TNF-a in order to allow differentiation and improve immunostimulatory capacity. As shown in Figure 1 , DC differentiated under these conditions were negative for the lineage markers CD3, CD14 and CD19 while expressing high levels of HLA-DR. As a result of exposure to the maturation stimulus TNF-a during differentiation, most DC acquired CD83 expression and downregulated CD1a, whereas only a minor DC population still retained a CD1a+/CD83-immature phenotype. 15, 19 Both costimulation molecules CD80/CD86 were upregulated. Since monocyte migration to the afferent lymph nodes is driven by the expression of chemokines and corresponding receptors on DC, we further investigated the chemokine receptors on the DC generated in vitro. Consistent with the acquisition of a mature phenotype, DC expressed CCR-7 but not the receptors for inflammatory chemokines CCR-1, CCR-2 and CCR-5, which are normally present on DC in immature state but are downregulated during maturation to allow DC migration from the inflammation site (Fig 2) . 20, 21 We also found that DC generated under these conditions were potent stimulators in mixed leukocyte reaction, with their efficacy being at least comparable to that of DC generated by the same cytokines in FCS-containing medium (data not shown).
DC transfection with total N43-EGFP RNA
In order to evaluate the feasibility of tumor RNA transfection into DC, we made use of a model closely mimicking the use of whole tumor RNA for DC loading. Thus, total RNA was isolated from the previously described N43-EGFP cell line (Gru¨nebach et al, submitted for publication), which was stably transfected with a vector encoding for the enhanced green fluorescent protein (EGFP). Total N43-EGFP RNA was transfected into DC by electroporation 18 and EGFP production in DC was monitored by flow cytometry. EGFP expression could be already detected in a subset of DC 14 h following transfection, peaked at about 72 h (Fig 3a,b) and progressively diminished, becoming undetectable 108 h following electroporation (Fig 3b) .
Induction of CTL by means of DC transfected with total SW480 RNA
Given the feasibility of total RNA transfection into serum-free generated DC, we investigated whether RNAtransfected DC could process antigens and present MHC Figure 1 Phenotype of DC generated under serum-free conditions. Adherent PBMC were cultured in X-VIVO 20 medium for 7 days in the presence of GM-CSF, IL-4 and TNF-a. Thereafter, cells were washed, stained and analyzed by flow cytometry. RNA-loaded DC for immunotherapy of colorectal cancer A Nencioni et al class I-restricted antigenic epitopes to induce a primary antitumor CTL response in vitro. To this aim, total RNA was isolated from the HLA-A2 positive colorectal cancer cell line SW480 and electroporated into DC generated from an HLA-A2 positive healthy donor. These DC were used as APC to stimulate autologous PBMC. As shown in Figure 4 , the generated CTL already exhibited lytic activity against SW480 cells after one cycle of restimulation (Fig 4a) . The lysis of SW480 cells could be blocked by a mAb specific for HLA class I, demonstrating that the cytolytic activity of the in vitroinduced CTL is MHC class I restricted (Fig 4a) . Interestingly, as shown in Figure 4b , these CTL also lysed autologous DC electroporated with SW480 RNA while sparing untreated DC, thus confirming the specificity of the lysis, and suggesting that tumor-RNA-transfected DC might represent a useful substitute for tumor cells as targets in CTL assays.
CTL induced with SW480 RNA recognize HCT116 and an RCC cell line
The lytic activity of CTL induced by DC loaded with SW480 total RNA was evaluated against different cell lines. Interestingly, we found that these CTL also recognized another HLA-A2 positive colorectal cancer line, HCT116, possibly because of the expression of shared tumor antigens (Fig 5a) . Moreover, also the HLA-A2 positive RCC line A498 was lysed by the generated CTL line. Conversely, no reactivity was observed against the EBV-immortalized HLA-A2 positive B-cells Croft.
To verify the crossreactivity of CTL induced against different colorectal carcinoma cell lines, total RNA was isolated from HCT116, and transfected into DC for CTL induction. Again, the generated CTL recognized the parental HCT-116 cells as well as SW480 cells but failed to lyse the control Croft B-cells (Fig 5b) . One restimulation was performed using similarly transfected DC after 7 days of culture. Cytolytic activity was determined on day 5 after restimulation in a standard 51 Cr-release assay. MHC I restriction of the observed lysis was assessed by blocking HLA class I molecules by an anti-MHC class I specific antibody. (b) autologous DC loaded with SW480 RNA and unloaded DC were included as targets in the assay.
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Discussion
As compared with immunization approaches targeting single-tumor antigens, inducing immune responses against a broad spectrum of antigens expressed by the patient's tumor might represent a more effective approach. This could lessen the chances for tumor immune escape because of Ag loss in mutant tumor cell clones. To this aim, DC transfected with total tumor RNA may represent a useful tool, since CTL against patient-specific tumor antigens are induced, which may recognize immunodominant Ags in the antitumor immune response. Several approaches for RNA delivery into DC have been explored, including passive pulsing, 7-12 lipofection and electroporation. 18 All these methods demonstrated to be effective for the induction of CTL recognizing the parental tumor cells, even if the transfection efficiency strongly varied among the different approaches. In line with a previous report by Van Tendeloo et al 17 we found that electroporation was the most effective approach to deliver RNA into DC as compared with lipofection or receptor-mediated RNA endocytosis (Gru¨nebach et al, submitted for publication), since it allows high transfection efficiencies with minimal loss of cell viability.
In the present study, we show that DC generated in vitro under serum-free conditions can be efficiently transfected with whole tumor RNA, and present tumorderived MHC class I-restricted antigenic epitopes from colorectal carcinoma cells for the induction of primary CTL responses in vitro. Our data confirm previous observations by Gilboa et al on the use of DC loaded with whole tumor RNA for the induction of antitumor CTL responses. [7] [8] [9] We report that DC differentiation induced under serum-free conditions in the presence of GM-CSF, IL-4 and TNF-a leads to the acquisition of a mature DC phenotype with high-level CD83 expression and upregulated costimulation molecules. Moreover, DC were found to express the chemokine receptor CCR-7 while exhibiting downregulated inflammatory chemokine receptors CCR-1, CCR-2 and CCR-5. Since CCR-7, together with the cognate chemokine ELC, drives DC traffic from the periphery to the afferent lymphoid tissues, 20, 21 culture conditions that upregulate its expression, as those we describe, may facilitate DC migration from the site of injection to the draining lymph nodes, where DC encounter with T cells takes place. 3 Once loaded with RNA isolated from colorectal colon cells, these DC elicited a potent CTL response against the parental cell lines, which could be already detected after one single restimulation cycle. As compared with the repeated restimulation cycles required to detect the cytotoxic activity of CTL induced by peptide epitopes, this represents a relevant result. Since we could detect EGFP protein expression for at least 72 h in DC transfected with N43-EGFP total RNA, it seems likely that the high efficiency in CTL induction might depend on the long-lasting presentation to T cells of tumorderived antigens by the transfected DC. Moreover, the presentation of several instead of single relevant tumorassociated T-cell epitopes might also contribute to speed up the induction of a polyclonal highly effective antitumor CTL response. Interestingly, the CTL generated by total RNA from SW480 also recognized another HLA-A2 positive colon cancer cell line, HCT116, and the RCC line A498. Moreover, CTL generated with HCT116 RNA crossreacted with SW480 cells. Since SW480, HCT116 and A498 share the expression of the tumorassociated antigen Her-2/neu (Brossart et al 22 ; AN, unpublished data), we tested whether Her-2/neu-derived epitopes would be recognized by the CTL induced with SW480 RNA, but no reactivity was detected against the immunogenic E75 and GP2 epitopes (data not shown). Hence, the observed crossreactivity may depend on other tumor antigens or other unidentified antigen epitopes.
In summary, our data indicate that DC transfected with total tumor-derived RNA are potent inducers of CTL responses against colorectal cancer cells, and might represent a suitable approach for the active specific immunotherapy of patients treated for this malignancy. 6 cells total RNA from HCT116 cells were used for CTL induction. Cytolytic activity was determined on day 5 after restimulation in a standard 51 Cr-release assay against HCT116, SW480 and Croft cells.
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The relevant rejection epitopes for these tumors still have to be determined and might be shared with other malignancies including RCC.
